Table 2 Tumor responses and survival outcomes.

From: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Efficacy

ITT (n = 141)

A (n = 4)

B (n = 20)

C (n = 46)

D (n = 10)

E (n = 46)

F (n = 6)

G (n = 9)

CRa, No. of patients (%)

4 (2.8)

0

0

2 (4.3)

1 (10.0)

1 (2.2)

0

0

PRa, No. of patients (%)

38 (27.0)

3 (75.0)

0

18 (39.1)

1 (10.0)

12 (26.1)

1 (16.7)

3 (33.3)

SD, No. of patients (%)

26 (18.4)

0

2 (10.0)

10 (21.7)

1 (10.0)

11 (23.9)

1 (16.7)

1 (11.1)

PD, No. of patients (%)

44 (31.2)

1 (25.0)

10 (50.0)

9 (19.6)

4 (40.0)

15 (32.6)

2 (33.3)

3 (33.3)

NAb, No. of patients (%)

29 (20.6)

0

8 (40.0)

7 (14.3)

3 (30.0)

7 (15.2)

2 (33.3)

2 (22.2)

Objective responsec

No. of patients

42

3

0

20

2

13

1

3

Percentage of patients (95% CI)

29.8 (22.4–38.1)

75.0 (19.4–99.4)

0

43.5 (28.9–58.9)

20.0 (2.5–55.6)

28.3 (16.0–43.5)

16.7 (0.4–64.1)

33.3 (7.5–70.1)

Disease controld

No. of patients

68

3

2

30

3

24

2

4

Percentage of patients (95% CI)

48.2 (39.7–56.8)

75.0 (19.4–99.4)

10.0 (1.2–31.7)

65.2 (49.8–78.6)

30.0 (6.7–65.3)

52.2 (36.9–67.1)

33.3 (4.3–77.7)

44.4 (13.7–78.8)

Median PFS (95% CI), month

3.4 (2.7–4.2)

3.4 (0–7.3)

1.9 (1.7–2.1)

4.6 (3.4–5.9)

2.0 (1.7–2.3)

3.4 (1.7–5.0)

1.2 (0–2.5)

3.0 (2.4–3.6)

Median OS (95% CI), month

10.7 (9.1–12.3)

16.7 (0–35.3)

6.1 (2.8–9.4)

16.1 (11.7–20.5)

6.2 (1.9–10.5)

10.1 (3.8–16.3)

2.7 (0–17.0)

4.5 (2.4–6.6)

  1. ITT Intention-to-treat, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not available, CI confidence intervals, PFS progression free survival, OS overall survival.
  2. aConfirmed responses only.
  3. bSignifies patients who discontinued therapy before the first postbaseline scan because of progressive disease or a treatment-related adverse event.
  4. cDefined as CR + PR.
  5. dDefined as CR + PR + SD.
Back to article page